http://doi.org/10.31288/oftalmolzh201036166

ANTERIOR ENDOGENOUS UVEITIS AND HLA-B27 ANTIGEN

G. D. Zhaboedov, N. V. Ivanova, A. I. Kopaenko

Kiev, Simferopol', Ukraine

The data of modern studies of etiology, pathogenesis, clinical course and treatment of HLA-B27- associated anterior uveitis (AU) are presented in the review paper. Special attention is paid to connection of HLA-B27- positive AU and systemic diseases associated with HLA antigen.

 

References

1.Жабоедов Г. Д., Копаенко А. И. Состояние сывороточного антиэндотоксинового иммунитета у больных увеитами // «Рецепт» Научно-практический журнал для фармацевтов и врачей. «VII съезд офтальмологов Республики Беларусь» — 2007. — С. 224- 228.

2.Жабоедов Г. Д., Иванова И. В., Копаенко А. И. Липополисахарид грамотрицательных бактерий как фактор риска развития передних эндогенных увеитов // Матеріали науково-практичної конференції офтальмологів з міжнародною участю «Філатовські читання». — 2009. — С. 109-110.

3.Копаенко А. И. Роль дисбаланса антиэндотоксинового иммунитета в патогенезе передних эндогенных увеитов // Проблеми сучасної медичної науки та освіти. — 2009. — № 2. — С. 77- 79.

4.Разумова И. Ю., Воробьева О. К., Годзенко А. А. Диа-гностика и лечение HLA-B27-ассоциированных увеитов // Вестник офтальмологии. — 2009. — № 3. — С. 15-18.

5.Разумова И. Ю., Годзенко А. А. HLA-B27-ассоциированные увеиты // Вестник офтальмологии. — 2009. — № 4. — С. 46- 50.

6.Accorinti M., Pirraglia M. P., Paroli M. P., et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease // Jpn J Ophthalmol. — 2007. — Vol. 51. — P. 191-196.
Crossref

7.Benitez-Del-Castillo J. M., Garcia-Sanchez J., Iradier T., Banares A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis // Eye — 2000. — Vol 14. — P. 340- 343.
Crossref

8.Breban M., Vignon E., Claudepierre P. et al: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study // Rheumatology — 2002. — Vol. 41. — P. 1280- 1285.
Crossref

9.Brophy S., Pavy S., Lewis P. Inflammatory eye, skin and bowel disease in spondyloarthritis: genetic, phenotypic and environmental factors // J Rheumatol. — 2001. — Vol. 28 (12). — P. 2667- 2673.

10.Calder V. L., Shaer B., Muhaya M. et al: Increased CD4 expression and decreased IL-10 in the anterior chamber in idiopathic uveitis // Invest Ophthalmol Vis Sci — 1999. — Vol. 40. — P. 2019-2024.

11.Chang J. H., McCluskey P., Wakefield D. Expression of toll-like receptor 4 and its associated lipopolysaccharide receptor complex by resident antigen-presenting cells in the human uvea // Invest Ophthalmol Vis Sci. — 2004 — Vol. 45. — P. 1871- 1878.
Crossref

12.Chang J. H., McCluskey P., Wakefield D. Acute ante¬rior uveitis and HLA-B27 // Survey of ophthalmology. —2005. — Vol. 50 (4). — P. 364-388.
Crossref

13.De Vos A. F., Klaren V. N., Kijlstra A. Expression of mul-tiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat // Invest Ophthalmol Vis Sci — 1994. — Vol. 35. — P. 3873- 3883

14.El-Shabrawi Y., Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corti-costeroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis // Ophthalmology. —2002.— Vol. 109. — P. 2342-2346.

15.Feltkamp TE: Ophthalmological significance of HLA asso-ciated uveitis // Eye. — 1990. — Vol. 4. — P. 839-844.

16.Huhtinen M., Karma A. HLA-B27 typing in the catego-rization of uveitis in a HLA-B27 rich population // Br J Ophthalmol. — 2000. — Vol. 84. — P. 413-416.

17.Jap A, Chee SP. Immunosuppressive therapy for ocular diseases // Curr Opin Ophthalmol. — 2008. — Vol. 19 (6). — P. 535-540.

18.Joseph A., Raj D., Dua H. S., et al: Infliximab in the treat-ment of refractory posterior uveitis // Ophthalmology. —2003.— Vol. 110. — P. 1449- 1453.

19.Khan M. A. HLA-B27 and its subtypes in world popu-lations // Curr Opin Rheumatol. —  1995. — Vol. 7. —P. 263-269.

20.Du L., Kijlstra A., Yang P. Immune response genes in uveitis // Ocul Immunol Inflamm. — 2009. — Vol. 17(4). —P. 249-256.

21.Kotake S., Furudate N., Sasamoto Y., et al: Characteristics of endogenous uveitis in Hokkaido, Japan // Graefes Arch Clin Exp Ophthalmol. — 1997. — Vol. 235. — P. 5-9.

22.Kuppermann B. D., Blumenkranz M. S., Haller J. A., et al. Randomized controlled study of an intravitreous dex-amethasone drug delivery system in patients with persis¬tent macular edema // Arch Ophthalmol. — 2007. — Vol. 125. — P. 309-317.

23.Lacomba M. S., Martin C. M., Chamond R. R., et al. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis // Arch Ophthal-mol. — 2000. — Vol. 118. — P. 768- 772.

24.Li Q., Peng B., Whitcup S. M., et al. Endotoxin enduced uveitis in the mouse: susceptibility and genetic control //Exp. Eye Res. — 1995. — Vol. 61 — P. 629-632.

25.Linssen A., Meenken C. Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis // Am J Ophthalmol. — 1995. — Vol. 120. — P. 351-361.

26.Linssen A., Rothova A., Valkenburg H. A., et al: The lifetime cumulative incidence of acute anterior uveitis in a normal population and its relation to ankylosing spondylitis and

histocompatibility antigen HLA-B27 // Invest Ophthalmol Vis Sci. — 1991. — Vol. 32. — P. 2568- 2578.

27.Mackensen F., Metea C. A., Planck S. R., Rosenbaum J. T., Endotoxin upregulates CCR7 and its ligands in the lymphatic-free mouse iris // Molecular Vision. — 2007. — Vol. 13. — P. 2209- 2213.

28.Maki-Ikola O., Lehtinen K., Toivanen P., Granfors K. Antibodies to Klebsiella pneumoniae, Esherichia coli and Proteus mirabilis in the sera of ankylosis spondylitis patients with / without and entheritis // Br J Rheumatol. — 1995. — Vol. 34. — P. 418- 420.

29.McCannel C. A., Holland G. N., Helm C. J., et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group // Am J Ophthalmol. — 1996. — Vol. 121. — P. 35- 46.

30.Mease P. J., Goffe B. S., Metz J., et al: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial // Lancet — 2000. — Vol. 356. — P. 385- 390.

31.Merril P. T., Kim J., Cox T. A., et al. Uveatis in the south-eastern United States // Curr Eye Res. —  1997. — Vol.16. — P. 865-874

32.Miyazaki A., Kitaichi N., Ohgami K. et al. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats // J Ocul Pharmacol Ther. — 2007. — Vol. 23 (4). — P. 343- 350.

33.Monnet D., Breban M., Hudry C., et al: Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases // Ophthalmol-ogy. — 2004. — Vol. 111. — P. 802- 809.

34.Niccoli L., Nannini C., Benucci M., et al. Long-term efficacy of infliximab inrefractory posterior uveitis of Behcet's disease: a 24-month follow-up study // Rheumatology. —

2007. — Vol. 46. — P. 1161-1164.

35.Pato E., Banares A., Jover J. A., et al: Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis // J Rheumatol. — 2000. — Vol. 27. — P. 2198-2202.

36.Power W. J., Rodriguez A., Pedroza-Seres M., Foster C. S. Outcomes in anterior uveitis associated with the HLA-B27 haplotype // Ophthalmology. —  1998. — Vol. 105. — P

1646-1651.

37.Rosenbaum J. T. HLA B27-associated diseases. in Pepose JS, Holland GN, Wilhelmus KR, eds Ocular Infection and Immunity. St Louis, Mosby-Yearbook, 1996, pp 475- 484.

38.Rothova A., Suttorp-van Schulten M. S., Frits Treffers W., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease // Br J Ophthal-mol — 1996. — Vol. 80. — P. 332- 336.

39.Ruiz-Moreno J. M., Thillaye В., de Kozak Y. Retino-choroidal changes in endotoxin-induced uveitis in the rat // Ophthalmic Res. — 1992. — Vol. 24. — P. 162- 168.

40.Saari K. M., Vilppula A., Lassus A., et al: Ocular inflammation in Reiter's disease after Salmonella enteritis // AmJOphthalmol. — 1980. — Vol. 90. — P. 63- 68.

41.Santos Lacomba M., Marcos Martin C, Gallardo Galera JM, et al Aqueous humor and serum tumor necrosis factoralpha in clinical uveitis // Ophthalmic Res. — 2001. — Vol. 33. — P. 251- 255.

42.Sfikakis P. P., Markomichelakis N., Alpsoy E., et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations // Rheumatology. — 2007. — Vol. 46. — P. 736- 741.

43.Sfikakis P. P., Theodossiadis P. G., Katsiari C. G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease // Lancet. — 2001. — Vol. 358. — P. 295¬296.
Crossref

44.Smit R. L., Baarsma G. S., de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital // Int Ophthalmol — 1993. — Vol. 17. — P. 71-76.

45.Sobrin L., Kim E. C., Christen W., et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease // Arch Ophthalmol. — 2007. — Vol. 125. — P. 895- 900.

46.Thurau S. R., Diedrichs-Mohring M., Fricke H., et al. Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis // Immunol Lett. — 1999. — Vol. 68. — P. 205- 212.

47.Tynjala P., Lindhal P., Honkanen V., et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis // Ann Rheum Dis. — 2007. — Vol. 66. — P. 548- 550.

48.Wakefield D., McCluskey P., Verma M., et al: Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis // Arthritis Rheum. — 1999. — Vol. 42. — P. 1894- 1897.

49.Wakefield D., Montanaro A., McCluskey P. Acute anterior uveitis and HLA-B27 // Surv Ophthalmol. — 1991. —Vol.36. — P. 223- 232.

50.Weiner H. L., Friedman A., Miller A., et al: Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens // Annu Rev Immunol — 1994. — Vol. 12. — P. 809-837.
Crossref